HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michael E. Gorton Jeffrey B. Kramer Gregory F. Muehlebach William A. Reed Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barnes, B. J. Articles by Reed, W. A. Search for Related Content PubMed PubMed Citation Articles by Barnes, B. J. Articles by Reed, W. A. Related Collections Electrophysiology - arrhythmias

Ann Thorac Surg 2006;82:1332-1337
© 2006 The Society of Thoracic Surgeons

---

Original Articles: Cardiovascular

Risk-Stratified Evaluation of Amiodarone to Prevent Atrial Fibrillation After Cardiac Surgery

^a Department of Pharmacy Practice, School of Pharmacy, The University of Kansas Medical Center, Kansas City, Kansas
^b Mid America Thoracic and Cardiovascular Surgery, Inc, The University of Kansas Hospital, Kansas City, Kansas

Accepted for publication April 24, 2006.

^_* Address correspondence to Dr Barnes, Pharmacy Practice, The University of Kansas Medical Center, Mail Stop 4047, 3901 Rainbow Blvd, Kansas City, KS 66160-7231 (Email: bbarnes{at}kumc.edu).

BACKGROUND: Amiodarone prophylaxis (AMP) reduces the prevalence of postoperative atrial fibrillation (POAF) after cardiac surgery. We investigated the impact of AMP on the frequency and duration of POAF, the intensive care unit and hospital length of stay, and its cost-effectiveness in a risk-stratified cohort.

METHODS: A retrospective, observational analysis of 509 patients who underwent cardiac surgery in 2003 was performed. Data sources included The Society of Thoracic Surgeons national database; medical and medication administration records; and the activity-based cost data from our institution. Risk stratification for POAF was determined using a validated risk index. Cost-effectiveness was determined from the hospital's perspective.

RESULTS: The mean patient age was 63 years, 27% were female, 80% underwent coronary artery bypass grafting, and 29% underwent valve surgery. When a risk-stratified evaluation was made, 50% of patients were at an elevated risk for having POAF develop. When compared with nonprophylaxed patients, those receiving AMP (59%) experienced less POAF (31% vs 22%; p = 0.027) and shorter durations of POAF (4.7 vs 2.7 days; p = 0.025). In the elevated-risk group, AMP clinically (but not significantly) reduced length of stay in the intensive care unit (101 vs 68 hours; p > 0.05) and post-procedural hospital length of stay (9.7 vs. 7.9 days, p > 0.05). In the elevated-risk group, AMP was robustly cost-effective in reducing POAF.

CONCLUSIONS: Amiodarone prophylaxis reduced the prevalence and duration of POAF. Baseline risk for POAF was a major determinant of the overall cost-effectiveness of AMP. The greatest cost savings with AMP was seen in patients at an elevated risk for POAF. These findings suggest the need for risk stratification when prescribing AMP.

This article has been cited by other articles:

				F. Roshanali, M. H. Mandegar, M. A. Yousefnia, F. Alaeddini, and B. Saidi Prevention of atrial fibrillation after coronary artery bypass grafting via atrial electromechanical interval and use of amiodarone prophylaxis Interactive CardioVascular and Thoracic Surgery, April 1, 2009; 8(4): 421 - 425. [Abstract] [Full Text] [PDF]

				A. Kourliouros, A. De Souza, N. Roberts, A. Marciniak, A. Tsiouris, O. Valencia, J. Camm, and M. Jahangiri Dose-Related Effect of Statins on Atrial Fibrillation After Cardiac Surgery Ann. Thorac. Surg., May 1, 2008; 85(5): 1515 - 1520. [Abstract] [Full Text] [PDF]

				P. A Howard and B. J Barnes Potential Use of Statins to Prevent Atrial Fibrillation After Coronary Artery Bypass Surgery Ann. Pharmacother., February 1, 2008; 42(2): 253 - 258. [Abstract] [Full Text] [PDF]